Published in Drug Metab Dispos on April 01, 1995
Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell (1999) 3.14
Methods to evaluate biliary excretion of drugs in humans: an updated review. Mol Pharm (2006) 0.98
Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy. J Transl Med (2011) 0.96
Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance. Cancers (Basel) (2014) 0.95
Clinical trials and progress with paclitaxel in ovarian cancer. Int J Womens Health (2010) 0.89
In vitro-in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6α-hydroxylation: effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearance. Eur J Clin Pharmacol (2011) 0.79
A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979). Br J Clin Pharmacol (2003) 0.76
Paclitaxel Enhances Carboplatin-DNA Adduct Formation and Cytotoxicity. Chem Res Toxicol (2015) 0.75
Nanosuspension delivery of paclitaxel to xenograft mice can alter drug disposition and anti-tumor activity. Nanoscale Res Lett (2014) 0.75
A Phase I/IIa Study of DHP107, a Novel Oral Paclitaxel Formulation, in Patients with Advanced Solid Tumors or Gastric Cancer. Oncologist (2017) 0.75
ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother (1998) 2.23
Alpha/beta interferons potentiate virus-induced apoptosis through activation of the FADD/Caspase-8 death signaling pathway. J Virol (2000) 2.11
The predictable relationship between plasma levels and dose during chronic propranolol therapy. Clin Pharmacol Ther (1978) 1.51
Food effects on propranolol systemic and oral clearance: support for a blood flow hypothesis. Clin Pharmacol Ther (1986) 1.31
Disposition and metabolism of the flavonoid chrysin in normal volunteers. Br J Clin Pharmacol (2001) 1.21
Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). Blood (2000) 1.20
Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res (2001) 1.20
Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia (2013) 1.20
Transport of quercetin and its glucosides across human intestinal epithelial Caco-2 cells. Biochem Pharmacol (1998) 1.18
"Loop" domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis. Cancer Res (1998) 1.14
Flavonoids, potent inhibitors of the human P-form phenolsulfotransferase. Potential role in drug metabolism and chemoprevention. Drug Metab Dispos (1996) 1.11
Naphthoxylactic acid after single and long-term doses of propranolol. Clin Pharmacol Ther (1979) 1.10
Extensive binding of the bioflavonoid quercetin to human plasma proteins. J Pharm Pharmacol (1998) 1.10
Effect of carbon substrates on rock phosphate solubilization by bacteria from composts and macrofauna. Curr Microbiol (2006) 1.08
CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood (2000) 1.06
Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther (1989) 1.05
The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy. Leukemia (2001) 1.03
Stereoselective binding of propranolol to human plasma, alpha 1-acid glycoprotein, and albumin. Clin Pharmacol Ther (1983) 1.01
Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in Caco-2 cells--potential role in carcinogen bioinactivation. Pharm Res (2001) 1.00
4-Hydroxypropranolol and its glucuronide after single and long-term doses of propranolol. Clin Pharmacol Ther (1980) 1.00
Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein. Res Commun Chem Pathol Pharmacol (1993) 1.00
Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia (2012) 0.98
Food-induced increase in propranolol bioavailability--relationship to protein and effects on metabolites. Clin Pharmacol Ther (1981) 0.98
The role of Apaf-1, caspase-9, and bid proteins in etoposide- or paclitaxel-induced mitochondrial events during apoptosis. Cancer Res (2000) 0.97
Extensive metabolism of the flavonoid chrysin by human Caco-2 and Hep G2 cells. Xenobiotica (1999) 0.97
Overexpression of Apaf-1 promotes apoptosis of untreated and paclitaxel- or etoposide-treated HL-60 cells. Cancer Res (1998) 0.96
Fate of the flavonoid quercetin in human cell lines: chemical instability and metabolism. J Pharm Pharmacol (1999) 0.95
Quercetin glucosides are completely hydrolyzed in ileostomy patients before absorption. J Nutr (2000) 0.93
Induction of UDP-glucuronosyltransferase by the flavonoids chrysin and quercetin in Caco-2 cells. Pharm Res (2000) 0.93
Quantitative account of propranolol metabolism in urine of normal man. Drug Metab Dispos (1985) 0.92
Quercetin and resveratrol potently reduce estrogen sulfotransferase activity in normal human mammary epithelial cells. J Steroid Biochem Mol Biol (2000) 0.90
Stimulatory as well as inhibitory effects of ethinyloestradiol on the metabolic clearances of propranolol in young women. Br J Clin Pharmacol (1996) 0.90
Stereoselective clearance and distribution of intravenous propranolol. Clin Pharmacol Ther (1984) 0.90
S-adenosyl-L-methionine: transcellular transport and uptake by Caco-2 cells and hepatocytes. J Pharm Pharmacol (2005) 0.89
Stereoselective sulphate conjugation of salbutamol by human lung and bronchial epithelial cells. Br J Clin Pharmacol (1996) 0.89
Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in the human hepatoma cell line hep G2. Drug Metab Dispos (2000) 0.88
Extensive and saturable accumulation of paclitaxel by the human platelet. Cancer Chemother Pharmacol (1995) 0.88
Hep G2 cell line as a human model for sulphate conjugation of drugs. Xenobiotica (1992) 0.87
Carbon dioxide is the major metabolite of quercetin in humans. J Nutr (2001) 0.87
Stereoselective oral bioavailability of (+/-)-propranolol in the dog. A GC-MS study using a stable isotope technique. Res Commun Chem Pathol Pharmacol (1979) 0.87
Presystemic and systemic glucuronidation of propranolol. Clin Pharmacol Ther (1979) 0.86
Stereoselective increase in propranolol bioavailability during chronic dosing in the dog. J Pharmacol Exp Ther (1983) 0.86
Bioactivation of the cooked food mutagen N-hydroxy-2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine by estrogen sulfotransferase in cultured human mammary epithelial cells. Carcinogenesis (1998) 0.86
Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors. Leukemia (2002) 0.85
Propranolol effects on membrane repolarization time in isolated canine Purkinje fibers: threshold tissue content and the influence of exposure time. J Pharmacol Exp Ther (1980) 0.84
Partial metabolic clearances as determinants of the oral bioavailability of propranolol. Br J Clin Pharmacol (1986) 0.84
New ring-hydroxylated metabolites of propranolol: species differences and stereospecific 7-hydroxylation. Drug Metab Dispos (1982) 0.84
Identification of major sulfate conjugates in the metabolism of propranolol in dog and man. Drug Metab Dispos (1983) 0.83
Quantitative metabolic fate of propranolol in the dog, rat, and hamster using radiotracer, high performance liquid chromatography, and gas chromatography-mass spectrometry techniques. Drug Metab Dispos (1983) 0.83
Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells. Leukemia (2001) 0.83
Stereochemical composition of propranolol metabolites in the dog using stable isotope-labeled pseudoracemates. Drug Metab Dispos (1984) 0.82
Influence of food on the intravenous and oral dose kinetics of propranolol in the dog. J Pharmacokinet Biopharm (1985) 0.82
Stereoselective sulphate conjugation of racemic terbutaline by human liver cytosol. Br J Clin Pharmacol (1990) 0.82
Separation of the enantiomers of intact sulfate conjugates of adrenergic drugs by high-performance liquid chromatography after chiral derivatization. J Chromatogr (1985) 0.82
Stereoselective ring oxidation of propranolol in man. Br J Clin Pharmacol (1984) 0.82
Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects. Clin Pharmacol Ther (1989) 0.81
Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors. Clin Cancer Res (1999) 0.81
Pharmacokinetics and metabolism of the pharmacologically active 4'-hydroxylated metabolite of propranolol in the dog. Drug Metab Dispos (1990) 0.81
O-methylated catechol-like metabolites of propranolol in man. Drug Metab Dispos (1978) 0.80
Stereoselective binding of the (-)-enantiomer of propranolol to plasma and extravascular binding sites in the dog. Drug Metab Dispos (1983) 0.80
Cytochrome P450 3A-mediated human liver microsomal taxol 6 alpha-hydroxylation. J Pharmacol Exp Ther (1994) 0.80
Stereoselective sulfate conjugation of racemic 4-hydroxypropranolol by human and rat liver cytosol. Drug Metab Dispos (1991) 0.80
'Loop' domain deletional mutant of Bcl-xL is as effective as p29Bcl-xL in inhibiting radiation-induced cytosolic accumulation of cytochrome c (cyt c), caspase-3 activity, and apoptosis. Int J Radiat Oncol Biol Phys (1999) 0.80
Quercetin, a potent and specific inhibitor of the human P-form phenosulfotransferase. Biochem Pharmacol (1995) 0.79
Increased clearance of propranolol and theophylline by high-protein compared with high-carbohydrate diet. Clin Pharmacol Ther (1987) 0.79
Rabbit hepatocytes in primary culture: preparation, viability and use in studies of propranolol metabolism. Hepatology (1990) 0.79
Stereoselective sulfate conjugation of 4-hydroxypropranolol and terbutaline by the human liver phenolsulfotransferases. Drug Metab Dispos (1992) 0.79
Selective induction of propranolol metabolism by smoking: additional effects on renal clearance of metabolites. J Pharmacol Exp Ther (1987) 0.79
Propranolol glucuronide cumulation during long-term propranolol therapy: a proposed storage mechanism for propranolol. Clin Pharmacol Ther (1979) 0.78
Chemical trapping of labile aldehyde intermediates in the metabolism of propranolol and oxprenolol. Res Commun Chem Pathol Pharmacol (1981) 0.78
Soft drugs. 21. Design and evaluation of soft analogs of propantheline. J Pharm Sci (1996) 0.78
Early kinetics of intravenous propranolol. Br J Clin Pharmacol (1982) 0.77
Soft drugs--XIV. Synthesis and anticholinergic activity of soft phenylsuccinic analogs of methatropine. Bioorg Med Chem (1993) 0.77
Assays of CYP2C8- and CYP3A4-mediated metabolism of taxol in vivo and in vitro. Methods Enzymol (1996) 0.77
Dexamethasone induction of taxol metabolism in the rat. Drug Metab Dispos (1995) 0.76
Pixel-based reconstruction (PBR) promising simultaneous techniques for CT reconstructions. IEEE Trans Med Imaging (1993) 0.76
Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia (2017) 0.75
Stereoselective delivery and actions of beta receptor antagonists. Biochem Pharmacol (1988) 0.75
Taxol metabolism in rat hepatocytes. Biochem Pharmacol (1993) 0.75
Propranolol, alprenolol and oxprenolol metabolism in the dog. Identification of N-methylated metabolites. Biomed Mass Spectrom (1981) 0.75
28-Homobrassinolide: a novel oxysterol transactivating LXR gene expression. Mol Biol Rep (2014) 0.75
Pharmacokinetics and metabolism of oral doses of a 4'-methylthio derivative of propranolol in man. Xenobiotica (1990) 0.75
Stereoselective sulfation of albuterol in humans. Biosynthesis of the sulfate conjugate by HEP G2 cells. Drug Metab Dispos (1993) 0.75
Pharmacokinetics and metabolism of a 4'-methylthio derivative of propranolol in the dog. Drug Metab Dispos (1989) 0.75
Stereoselective metabolism of RS-albuterol in humans. Clin Rev Allergy Immunol (1996) 0.75
Induction of propranolol metabolism in the Hep G2 human hepatoma cell line. J Pharm Pharmacol (1992) 0.75
Human phenol sulfotransferases: chiral substrates and expression in Hep G2 cells. Chem Biol Interact (1994) 0.75
Improved bacterial expression of the human P form phenolsulfotransferase. Applications to drug metabolism. Drug Metab Dispos (1996) 0.75
Immunoaffinity isolation of the sulfate conjugate of 4'-hydroxypropranolol from plasma. J Chromatogr (1993) 0.75
Sulphonation of N-hydroxy-2-acetylaminofluorene by human dehydroepiandrosterone sulphotransferase. Xenobiotica (2000) 0.75
Stereoselective accumulation of the beta-receptor blocking drug atenolol by human platelets. Chirality (1991) 0.75
Histology and cytology of liver in Indian desert gerbil (Meriones hurrianae, Jerdon) following radiocalcium (Ca-45) administration. Radiobiol Radiother (Berl) (1980) 0.75